STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial

A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
Source
Stat News
Opens original article in a new tab



